Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2).

Atalay F, Ateşoğlu EB.

Indian J Hematol Blood Transfus. 2016 Mar;32(1):46-53. doi: 10.1007/s12288-015-0509-2.

PMID:
26855506
2.

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.

Zeidan AM, Kharfan-Dabaja MA, Komrokji RS.

Curr Opin Hematol. 2014 Mar;21(2):123-30. doi: 10.1097/MOH.0000000000000016. Review.

3.

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.

Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M.

Leuk Lymphoma. 2014 Jun;55(6):1431-4. doi: 10.3109/10428194.2013.840777. No abstract available.

4.

Current therapy of myelodysplastic syndromes.

Zeidan AM, Linhares Y, Gore SD.

Blood Rev. 2013 Sep;27(5):243-59. doi: 10.1016/j.blre.2013.07.003. Review.

5.

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.

Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum W.

Leuk Lymphoma. 2014 Jun;55(6):1304-8. doi: 10.3109/10428194.2013.833333.

6.

Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.

Hodges TR, Choi BD, Bigner DD, Yan H, Sampson JH.

J Neurosurg. 2013 Jun;118(6):1176-80. doi: 10.3171/2013.3.JNS122282. Review.

7.

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.

O'Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO, Sekeres MA, Dennis M, Venditti A, Berry DA, Jacobsen TF, Staudacher K, Bergeland T, Giles FJ.

Br J Haematol. 2012 Sep;158(5):581-8. doi: 10.1111/j.1365-2141.2012.09186.x.

8.

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.

Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, Ejerblad E, Garelius H, Dufva IH, Jansson M, Jädersten M, Kjeldsen L, Linder O, Nilsson L, Vestergaard H, Porwit A, Grønbæk K, Hellström-Lindberg E.

Haematologica. 2011 Jul;96(7):963-71. doi: 10.3324/haematol.2010.039669. Erratum in: Haematologica. 2011 Aug;96(8):1240. Lindberg, Eva Hellström [corrected to Hellström-Lindberg, Eva].

9.

DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.

Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, Wiemels JL, Nelson HH, Karagas MR, Wrensch MR, Kelsey KT, Wiencke JK.

J Natl Cancer Inst. 2011 Jan 19;103(2):143-53. doi: 10.1093/jnci/djq497.

10.

Targeting DNA methylation for epigenetic therapy.

Yang X, Lay F, Han H, Jones PA.

Trends Pharmacol Sci. 2010 Nov;31(11):536-46. doi: 10.1016/j.tips.2010.08.001. Review.

11.

5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Sutherland MK, Yu C, Anderson M, Zeng W, van Rooijen N, Sievers EL, Grewal IS, Law CL.

MAbs. 2010 Jul-Aug;2(4):440-8.

Items per page

Supplemental Content

Support Center